# OMEICOS Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/omeicos-therapeutics

- Industry: Biotechnology
- Headquarters: Berlin, Germany
- Website: www.omeicos.com
- Total disclosed funding: $35M
- Latest round: Series C (Nov 2, 2018)
- Investors on record: 11

## About

Based in Berlin, Germany, OMEICOS Therapeutics GmbH focuses on developing innovative therapies for cardiovascular, inflammatory, and mitochondrial diseases, addressing significant unmet medical needs in healthcare.Founded in 2013 in Berlin, Germany, OMEICOS Therapeutics GmbH specializes in therapeutic advancements. The company has secured a total of EUR 17.000 mn over various funding rounds, including its latest GRANT of EUR 2.500 mn from the Federal Ministry of Education and Research. CEO Robert Fischer leads the firm, which has successfully completed 9 deals to date.OMEICOS Therapeutics specializes in developing therapies targeting cardiovascular, inflammatory, and mitochondrial diseases, particularly with its lead product, OMT-28. This product has shown efficacy in clinical trials, especially in a Phase 2 study for patients with atrial fibrillation, demonstrating a strong safety profile and notable impacts on biomarkers like GDF-15 and IL-6. The company is currently progressing OMT-28 through further testing in a Phase II proof-of-concept study for myopathy and cardiomyopathy in individuals with primary mitochondrial diseases. OMEICOS primarily serves the European and North American markets, working with healthcare providers and clinical researchers to enhance patient outcomes in serious health conditions.OMEICOS Therapeutics generates revenue through partnerships and clinical collaborations, engaging predominantly in B2B transactions with healthcare institutions and clinical trial sponsors. As OMT-28 advances through clinical trials, the company may seek further commercialization agreements, potentially involving licensing deals or joint ventures with pharmaceutical companies focused on cardiovascular treatments. The revenue model includes milestone payments linked to the progress of clinical trials and product launches, underscoring the commitment of partners to the successful development of OMT-28 and subsequent products.OMEICOS Therapeutics plans to utilize recent funding, including an undisclosed amount from new investor MaasInvest, to support the advancement of OMT-28 and explore new product launches. The company aims to expand its market presence in Europe and North America, with specific initiatives planned for the next two years. The funding will facilitate ongoing clinical trials and potential commercialization strategies to enhance the availability of their therapeutic solutions.

## Funding rounds

- Series C, Nov 2, 2018, $19M — KfW Banking Group, Forbion, Vesalius Biocapital, SMS Group GmbH, High-Tech Gruenderfonds, Remiges Ventures, VC Fonds Technologie Berlin, The Falck Revocable Trust
- Series B, Oct 4, 2017 — Remiges Ventures
- Series B, Dec 20, 2016, $8.7M — KfW Banking Group, Vesalius Biocapital, SMS Group GmbH, High-Tech Gruenderfonds, Ascenion GmbH, Remiges BioPharma Fund, VC Fonds Technologie Berlin, The Falck Revocable Trust
- Series A, Apr 15, 2015, $6.6M — KfW Banking Group, IBB Ventures, Vesalius Biocapital, SMS Group GmbH, High-Tech Gruenderfonds
- Seed, Nov 18, 2012 — High-Tech Gruenderfonds

## Investors

- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Seed, Series A, Series B, Series C
- KfW Banking Group — Series A, Series B, Series C
- IBB Ventures (https://capitalatlas.ai/funds/ibb-ventures) — Series A
- Vesalius Biocapital (https://capitalatlas.ai/funds/vesalius-biocapital) — Series A, Series B, Series C
- SMS Group GmbH — Series A, Series B, Series C
- Ascenion GmbH — Series B
- Remiges BioPharma Fund — Series B
- VC Fonds Technologie Berlin — Series B, Series C
- The Falck Revocable Trust — Series B, Series C
- Remiges Ventures (https://capitalatlas.ai/funds/remiges-ventures) — Series B, Series C
- Forbion (https://capitalatlas.ai/funds/forbion) — Series C